# Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

> **NCT06609304** · PHASE4 · RECRUITING · sponsor: **Zhengzhou University** · enrollment: 20 (estimated)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **BIOLOGICAL:** Axicabtagene Ciloleucel

## Key facts

- **NCT ID:** NCT06609304
- **Lead sponsor:** Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2026-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06609304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06609304, "Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06609304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*